TrialInternational journal of hematology2025

Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.

Tatsunori Goto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.